Gene test may predict chemo side effects in breast cancer patients
NCT ID NCT00953537
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed study looked at whether a deficiency in the DPD enzyme can predict severe side effects from the chemotherapy drug capecitabine in women with metastatic breast cancer. Researchers analyzed blood samples from 303 participants to see if genetic differences could help doctors plan safer treatment. The goal was to reduce risks like diarrhea and hand-foot syndrome by identifying vulnerable patients beforehand.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
capecitabine
What this could lead to
If successful, this could help doctors identify patients at risk for severe side effects from capecitabine, allowing safer, more personalized treatment plans.
What could go wrong
This is a small, completed pilot study, so results may not apply broadly. The focus is on predicting toxicity, not improving outcomes, and the approach may not be ready for routine use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Antoine Lacassagne
Nice, 06189, France